The in situ injection of 1-MT@OMV-Mal effectively overcomes the immune suppression induced by IDO on effector T cells infiltrating the tumor, resulting in significant inhibition of both primary and distant tumors (217). The gene discussed is IDO1; the disease is neoplasm.